Chronic myelogenous leukemia, version 1.2015.

Published

Journal Article

Chronic myelogenous leukemia (CML) is usually diagnosed in the chronic phase. Untreated chronic phase CML will eventually progress to advanced phase (accelerated or blast phase) CML. Tyrosine kinase inhibitors (TKIs) have been shown to induce favorable response rates in patients with accelerated and blast phase CML. The addition of TKIs to chemotherapy has also been associated with improved outcomes in patients with blast phase CML. Allogeneic hematopoietic stem cell transplant remains a potentially curative option for patients with advanced phase CML, although treatment with a course of TKIs will be beneficial as a bridge to transplant. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with advanced phase CML.

Full Text

Duke Authors

Cited Authors

  • O'Brien, S; Radich, JP; Abboud, CN; Akhtari, M; Altman, JK; Berman, E; Curtin, P; DeAngelo, DJ; Deininger, M; Devine, S; Fathi, AT; Gotlib, J; Jagasia, M; Kropf, P; Moore, JO; Pallera, A; Reddy, VV; Shah, NP; Smith, BD; Snyder, DS; Wetzler, M; Gregory, K; Sundar, H

Published Date

  • November 2014

Published In

Volume / Issue

  • 12 / 11

Start / End Page

  • 1590 - 1610

PubMed ID

  • 25361806

Pubmed Central ID

  • 25361806

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2014.0159

Language

  • eng

Conference Location

  • United States